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Background & Aims: Histopathology is an emerging treatment target in ulcerative colitis
(UC) clinical trials. We aim to provide guidance on standardizing biopsy collection protocols,
identifying optimal evaluative indices, and defining thresholds for histologic response and
remission after treatment.
Methods: An international, interdisciplinary expert panel of 19 gastroenterologists and
gastrointestinal pathologists was assembled. A modified RAND/University of California Los
Angeles appropriateness methodology was used to address relevant issues. A total of 138
statements were derived from a systematic review of the literature and expert opinion. Each
statement was anonymously rated as appropriate, uncertain, or inappropriate using a 9-point scale.
Survey results were reviewed and discussed prior to a second round of voting.

Author Manuscript

Results: Histologic measurements collected using a uniform biopsy strategy are important for
assessing disease activity and determining therapeutic efficacy in UC clinical trials. Multiple
biopsy strategies were deemed acceptable, including segmental biopsies collected according to
the endoscopic appearance. Biopsies should be scored for architectural change, lamina propria
chronic inflammation, basal plasmacytosis, lamina propria and epithelial neutrophils, epithelial
damage, and erosions/ulcerations. The Geboes Score, Robarts Histopathology Index, and Nancy
Index were considered appropriate for assessing histologic activity; use of the modified Riley
Score and Harpaz Index were uncertain. Histological activity at baseline should be required
for enrollment, recognizing this carries operational implications. Achievement of histologic
improvement or remission were considered appropriate and realistic therapeutic targets. Current
histological indices require validation for pediatric populations.
Conclusions: These recommendations provide a framework for standardized implementation of
histopathology in UC trials. Additional work is required to address operational considerations and
areas of uncertainty.

Author Manuscript

SHORT SUMMARY
We convened an interdisciplinary expert panel to create a standardized framework for collecting
biopsies, interpreting histologic disease activity, and defining histologic response and remission
for UC clinical trials.

Keywords
Geboes Score; histology; inflammatory bowel disease; Nancy Index; Robarts Histopathology
Index

INTRODUCTION
Author Manuscript

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that results from
a dysregulated mucosal immune response.1, 2 Historically, medical therapy has been
aimed at improving patient symptoms, notwithstanding that achieving clinical remission
alone has proved insufficient to change the natural history of UC. The advent of more
effective treatments has facilitated the shifting of therapeutic targets towards normalization
of objective measures of disease activity using a “treat-to-target” approach.3 However,
the precise target of medical therapy remains contentious since comparison of relevant
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treatment targets has not been assessed in a controlled manner. While achieving endoscopic
remission is currently recommended as the goal in clinical practice,3 histopathologic
improvement has emerged as a potential treatment target as it is a more sensitive measure
of mucosal inflammation. Furthermore, several observational studies have shown that
histological remission is associated with lower rates of disease-related complications
including hospitalization, corticosteroid use, and colectomy, compared to either resolution
of symptoms or endoscopic improvement alone.4-7 Finally, measuring histologic activity is
also conceptually advantageous because the pathophysiology of inflammatory changes in
UC begin at the level of the colonic mucosa.

Author Manuscript
Author Manuscript

Despite these potential benefits, substantial barriers exist to the use of histopathology as
an outcome measure in clinical trials and practice. First, there is an absence of controlled
data on which to base decisions. Second, while multiple indices for measuring histologic
activity in UC have been developed, there are no widely accepted endpoint definitions,
either data-driven or determined by consensus, for histologic response and remission.8
Third, the operating properties of the different histology indices require further comparative
evaluation.9 Fourth, there is a lack of standardization with respect to appropriate biopsy
collection protocols. Specifically, it is uncertain how many biopsies are required or where
biopsies should be taken to obtain optimal results. Fifth, there are minimal data to
explore the impact of histological remission on long-term clinical outcomes. Despite these
uncertainties, the United States Food and Drug Administration has approved a drug label for
mucosal healing for ustekinumab using a combined endpoint of endoscopic and histological
healing.10 Recognizing that histology samples are now routinely collected in UC clinical
trials and multiple novel therapeutic agents are in the development pipeline, consensus
recommendations that address heterogeneity in biopsy acquisition, measurement tools and
item definitions for histologic activity, and thresholds for classifying histologic response
and remission are urgently needed. The European Crohn’s and Colitis Organization recently
provided recommendations for histology evaluation in routine clinical practice, however,
detailed guidance for clinical trials outside of using validated instruments was missing.11
Therefore, we assembled an interdisciplinary panel of experts and conducted a multiple
round consensus process using modified RAND/University of California Los Angeles
(UCLA) appropriateness methodology with the intent of generating recommendations for
standardization of histologic assessment in UC clinical trials.

MATERIALS AND METHODS
Systematic literature review

Author Manuscript

We previously conducted a Cochrane systematic review evaluating histologic scoring
systems in UC and specifically updated the review for this exercise.9 The updated systematic
review searched PubMed (1966), EMBASE (Ovid, 1947), MEDLINE (Ovid, 1946), and
the Cochrane Library (CENTRAL) up to March 1, 2020 without language restriction.
The primary aim was to identify definitions, instruments, and operating properties of
histology indices used for the assessment of patients with UC. All study designs (i.e.,
randomized controlled trials, cohort studies, and case series) were considered for inclusion.
The full search terms are summarized in Supplementary Appendix 1. A recursive search of
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bibliographies of relevant review articles was also performed, as was a manual review of
abstracts submitted to Digestive Disease Week, United European Gastroenterology Week,
and the European Crohn’s and Colitis Organization Scientific Meeting from 2014 to 2019.
Eligible studies evaluated a histology index for measuring disease activity in patients with
UC as confirmed by conventional clinical, endoscopic, and histologic criteria. Citations and
abstracts were independently screened, and data were extracted by two reviewers (AA and
RS). Disagreements were resolved by consensus or arbitration by a separate reviewer (CM).

Author Manuscript

Histologic scoring data from eligible studies was collected. The reliability, validity,
responsiveness, and feasibility of UC histology indices were evaluated. Reliability was
assessed by measurement of intra- and inter-rater reliability, test-retest reliability, or
internal consistency. Validity was evaluated for content, criterion, and construct validity.
Responsiveness was defined by the ability of the index to measure change after a period
in which histologic variation could reasonably be expected (e.g., following a treatment
of known efficacy). Feasibility was evaluated based on rater assessment of ease of
administration and time needed for scoring. A summary of the key results of the systematic
review which informed the RAND/UCLA survey are presented narratively.
Expert consensus process

Author Manuscript

Expert Recruitment—An interdisciplinary, international panel of experts was selected
to participate, including ten gastroenterologists and nine pathologists, specializing in IBD,
from four countries including the United States, Canada, the Netherlands, and Australia.
Participants were selected based upon publication record and expertise in clinical trial design
and drug development, clinical epidemiology, or histopathology in UC. The final selection
of panelists was performed by CM, RKP, BGF, and VJ. Colorectal surgeons were not
included, given that the focus of this consensus was on determining definitions and histology
targets in UC clinical trials of medical therapy.
Modified RAND/UCLA Appropriateness Methodology—A modified RAND/UCLA
appropriateness methodology that incorporated a Delphi panel approach with iterative
rounds of voting and discussion to combine the best available evidence with expert
experience was used.12 The modified RAND/UCLA approach evaluated face validity (i.e.,
the extent to which an item addresses the concept it purports to measure) and feasibility of
items identified in the systematic review, as well as additional items derived from expert
panelist opinion.

Author Manuscript

Two rounds of voting occurred. In the first introductory panel meeting, items identified
by the systematic review were summarized, and panelists were given an opportunity to
generate additional relevant statements. The complete list of statements was then circulated
via an online survey and all panelists anonymously rated each item by appropriateness on
a 9-point scale (1=inappropriate, 9=highly appropriate). Each survey item was classified
as inappropriate, uncertain, or appropriate based on the median panel rating and degree of
panel disagreement, as defined by the RAND/UCLA manual: inappropriate (median score
1 to 3.5 without disagreement); uncertain (median score 3.5 to 6.5 without disagreement
or any median score with disagreement); and appropriate (median score 6.5 to 9 without
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disagreement). Disagreement was defined as having at least six or more panelists in each of
the lowest (1-3) and highest (6-9) three-point regions.
Results of the first-round survey were then collated, distributed to panelists, and reviewed
in a moderated teleconference, with the aim of identifying areas of disagreement on item
appropriateness and rationale for responses. The survey was then revised based on the
panel meeting to improve clarity prior to re-circulation and second round voting. Statement
appropriateness for the second round of voting was scored as described above.

RESULTS
Systematic Review

Author Manuscript

A total of 7776 records were identified. After removing duplicates, 5205 citations were
screened, and 192 records underwent full-text review. A total of 113 reports of 40 studies
were included (Supplementary Figure 1). The Geboes Score, Robarts Histopathology Index,
and Nancy Index were the most studied evaluative indices. Most indices evaluated similar
items, including the presence of acute or chronic inflammatory infiltrates, the presence of
neutrophils (especially in the lamina propria or epithelium), and structural changes such
as crypt destruction or ulceration. The operating properties of these indices, including the
inter- and intra-rater reliability, measures of content, construct, and criterion validity, and
responsiveness are summarized Supplementary Tables 1-5.
Item Generation and Survey

Author Manuscript

Results from the systematic review were used to inform the survey statements. Items were
grouped according to the following topics: standardization of biopsy acquisition, histologic
items/indices for measurement of disease activity in UC clinical trials, configuration of
clinical trial endpoints in UC, and considerations for pediatric and adolescent participants
with UC. The first survey consisted of 125 items. After a moderated teleconference to
review the results, a final survey consisting of 138 items was circulated. Overall, 100 (72%)
items were considered appropriate, 35 (25%) uncertain, and 3 (2%) inappropriate. Key
items, including panelist ratings, are summarized in Tables 1 to 3.
Appropriateness of Items

Author Manuscript

General Considerations and Standardization of Biopsy Acquisition—The panel
determined that histologic measurements, collected using a uniform biopsy strategy, are
important for assessment of disease activity and determination of therapeutic efficacy in
UC clinical trials (Table 1). Although the panel recognized that there may be cases where
endoscopic and histologic disease activity is discordant, it was determined that endoscopic
appearance of the mucosa should guide the site of biopsy procurement. Biopsies should
be taken from the ulcer edge if ulcer(s) are present, or from the most abnormal area in
macroscopically inflamed mucosa without ulceration, or randomly from endoscopically
normal mucosa. Standard forceps are appropriate for biopsy acquisition.
At screening, segmental biopsies taken from the rectum, sigmoid, descending, transverse,
and ascending colon were deemed to be appropriate if a colonoscopy was performed;
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whereas three segment biopsies from the descending, sigmoid colon and rectum are
appropriate for sigmoidoscopy. Some panelists felt this strategy may not be feasible given
operational implications for histopathology reading volume. Alternative strategies of taking
biopsies from the worst affected area at either 0 to 25 cm or 15 to 25 cm from the anal
verge were also considered appropriate. However, panelists acknowledged that the strategy
of using a specific distance is: 1) subject to measurement error due to looping of the
endoscope; 2) may exclude evaluation of the rectum; 3) discordant with the endoscopic
evaluation that accounts for all of the mucosa; 4) problematic because the healing of UC
after medical treatment may be patchy; and 5) limited sampling may be susceptible to
confounding by non-UC pathology such as ischemia or segmental colitis associated with
diverticular disease.

Author Manuscript

For induction trials, the panelists deemed biopsy procurement at 8 to 12 weeks after
randomization to be appropriate, whereas there was uncertainty between 14 to 20 weeks.
In maintenance trials, biopsy procurement at week 52 relative to randomization was deemed
to be appropriate. At follow-up, the panelists determined that biopsies should still be taken
from the worst affected area in each segment, even if that area was different compared to
baseline, although some panelists endorsed the importance of obtaining biopsies from both
the worst affected area as well as the same area sampled at baseline.

Author Manuscript

Biopsies should be fixed in formalin for a minimum of 6 hours and maximum of 36 hours
to ensure optimal tissue samples for routine hematoxylin and eosin (H&E) staining and
subsequent molecular and immunohistochemistry (IHC) studies. The panelists identified
proper orientation of the biopsies in the tissue block after procurement as a necessary
step for accurate scoring, such that the long axis of the colonic crypts is visualized in
the tissue section. The panel voted that H&E staining is sufficient for measuring disease
activity. Although it was recognized that IHC can provide valuable additional information,
there was uncertainty as to whether IHC should be routinely required to measure disease
activity. Specifically, it was uncertain if myeloperoxidase (MPO) expression by IHC should
be assessed in UC clinical trials as it would add time and expense and could potentially
overestimate histologic activity as MPO is not expressed by neutrophils only.

Author Manuscript

Histologic Items and Indices to Measure Disease Activity in UC Clinical
Trials—Histologic items deemed appropriate for disease measurement included: degree
of architectural change/distortion, lamina propria chronic inflammation (lymphocytes and
plasma cells), basal plasmacytosis, lamina propria neutrophils, epithelial neutrophils,
epithelial damage (surface epithelial injury and crypt destruction), and presence of erosions
and ulcerations (Table 2). When evaluating chronic inflammatory infiltrate, the panel
determined that both basal plasmacytosis and lamina propria cellularity should be assessed.
There was uncertainty regarding the appropriateness of quantifying and measuring lamina
propria eosinophils. For each item to be measured, the panel determined it was appropriate
for the biopsy fragment generating the worst score for that item to be scored, rather than
basing the score on the average involvement across all fragments.
Several histology indices were considered. The Geboes Score was considered appropriate
for assessing histologic activity in UC and classifying active disease, although the panel
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acknowledged that it was not specifically designed for measuring change in histologic
activity due to the hierarchical scoring. Similarly, panelists were uncertain if converting
the Geboes Score to a continuous 0 to 22 scale was appropriate for this purpose. The
panelists were asked to evaluate both the original descriptors of the Geboes Score as well
as an alternate definition adapted to use more quantitative cut-offs (Supplementary Table
6). Panelists rated both the original and adapted definitions as appropriate. The Robarts
Histopathology Index and the Nancy Index were determined to be appropriate for assessing
histologic disease activity in UC, classifying active versus inactive disease, and measuring
change in histologic disease activity after treatment. The panelists were uncertain if the
modified Riley Score or the Harpaz Index are appropriate instruments to use in UC clinical
trials.

Author Manuscript

Configuration of Clinical Trial Endpoints and Outcome Definitions—There was
agreement that a minimum degree of histological activity at baseline as defined by a
Geboes Score of ≥ 3.1 (minimum of neutrophilic inflammation in the epithelium), a Robarts
Histopathology Index score of ≥ 4, or Nancy Index score of ≥ 2 should be required for
enrollment in clinical trials; despite the fact that this is not routinely performed in current
trials (Table 3). While this recommendation was deemed appropriate for trials of mild-tomoderate UC (in order to rigorously confirm active inflammation), there was uncertainty if
minimum histological activity should also be required in patients with moderate-to-severe
disease.

Author Manuscript
Author Manuscript

Achievement of histologic remission or histologic improvement, or measurement of change
in histology scores were all voted to be realistically achievable and appropriate endpoints
for use in clinical trials. There was agreement that histologic remission should be defined
by the absence of neutrophilic inflammation in the mucosa, both at the end of induction
and maintenance therapy. The panel voted that a ≥ 7-point reduction in the Robarts
Histopathology Index from baseline or ≥ 1-point reduction in the Nancy Index from baseline
were the most appropriate definitions for histologic improvement. Histologic improvement
as defined by a Geboes Score of ≤ 3.1 was also considered appropriate. The definition of
mucosal healing based on endoscopic improvement and histologic remission was determined
to be appropriate, in accordance with recommendations from regulatory agencies. The use
of histology as either a primary or secondary endpoint in UC clinical trials was voted
as appropriate, although we acknowledge that the use of histology as a primary endpoint
may not be acceptable to regulatory authorities. However, it was uncertain whether direct
comparison of the biopsies should be performed when assessing change in disease activity
between time points for a given subject if the pathologist is blinded to timepoint and
treatment assignment.
Several histologic treatment targets were considered. Histologic remission, defined as the
absence of neutrophilic inflammation in the mucosa, with or without normal to mild
increase in lamina propria chronic inflammation, was voted to be an appropriate and
realistic histologic target in UC. However, there was uncertainty if it was realistic to achieve
improvement in lamina propria chronic inflammation at the end of induction therapy. The
panel was also uncertain if additionally targeting a normal to mild increase in lamina
propria eosinophils for histologic remission is appropriate or realistic. There was uncertainty
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if complete histologic normalization is an appropriate therapeutic target as there may be
residual chronic architectural distortion, and there was agreement that is not a realistic target
based upon the efficacy of current therapies.
Considerations for Pediatric and Adolescent UC Patients—While the panel agreed
that histological disease indices developed for adult patients are currently appropriate to
use in adolescent and pediatric patients, there was recognition that there are potentially
different pathological features, including more patchy histologic involvement, more frequent
pancolonic disease extent, and potentially different patterns of healing in pediatric compared
to adult patients. The panel identified greater sampling variation as a potential confounder
of thresholds for histologic outcomes in children, and a need to validate histologic indices in
this population.
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DISCUSSION
Histopathology is an increasingly important modality for assessing disease activity in
patients with UC. As most drug development programs routinely incorporate biopsy
collection at enrollment and endpoint evaluation, the development of a standardized
approach to assessing histopathology in clinical trials is needed. This expert panel developed
a framework for implementing histopathology in UC trials, including recommendations for
standardization of biopsy procurement and handling protocols, histologic items, and indices
appropriate for measuring disease activity, and configuration of histopathology endpoints
and outcome definitions.
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Panelists agreed that a uniform biopsy strategy is needed to optimally measure disease
activity. Historically in UC trials, two biopsies collected from the area of worst inflammation
~15 to 25 cm from the anal verge were used to measure histologic endpoints.13 However,
several potential problems with this paradigm were identified: 1) patients with UC may
have patchy healing after treatment; 2) it is unclear if distal biopsies adequately reflect
proximal inflammation in patients with more extensive disease; 3) this convention can
result in biopsy sampling from an area that does not correlate with endoscopic assessment,
which is scored based on the most inflamed segment observed14, 15 ; and 4) this strategy
ignores inflammation in the rectum, which is typically the last segment in the colon to
heal. This discrepancy may be further compounded as some trial programs require full
colonoscopy rather than sigmoidoscopy alone. Notably, the panel voted that taking either
3- or 5-segment biopsies (depending on the extent of the procedure) as appropriate. While
this strategy would better capture heterogeneity in histologic disease activity, there are
practical implications to taking segmental biopsies both at baseline and follow-up, including
increased operational burdens for proper biopsy labeling and handling, slide preparation
and fixation, central reader pathologist assessment, limitation to procurement of additional
biopsies for biomarker analyses and procedural burden to patients.
Panelists agreed that, at follow-up, it is appropriate to target biopsies at the same area as
baseline procurement, in addition to sampling the area of worst endoscopic inflammation,
accepting that these may be different locations. It should be stressed that such an approach
risks bias towards finding no difference in histological inflammation between baseline and
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follow-up. Additionally, there are practical limitations to identifying the previous biopsy
site, and although generally considered safe, it was agreed that endoscopic tattooing
was inappropriate for this purpose.16 Two to four biopsies per segment were considered
appropriate, and this is consistent with a recent study demonstrating that blinded evaluation
of two or three biopsies could reliably assess histologic disease activity in a single colonic
segment using the Robarts Histopathology Index.17 When multiple biopsies are taken, the
panel determined each item should be scored based on the fragment that exhibits the worst
score for each item, rather than averaging scores across fragments. This recommendation
was primarily driven by considerations of maximizing responsiveness within a clinical trial
to identify potentially efficacious agents. In a situation analogous to central endoscopic
assessment based on the worst mucosal appearance, which has resulted in low endoscopic
placebo rates,18 there were concerns that averaging histology scores across fragments may
result in smaller treatment effect sizes, especially if biopsies are taken from areas of normal
mucosa.
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The panel determined that a minimum degree of histologic activity should be required at
baseline for trial enrollment (Geboes Score ≥ 3.1, Robarts Histopathology Index ≥ 4, Nancy
Index ≥ 2). To date, this practice has not been routinely implemented. However, it was
ultimately considered that if histologic response or remission is to be adopted as a primary
or secondary trial endpoint, patients should be required to have microscopic disease activity
at baseline to meaningfully report and interpret these outcomes. The panel recognized that
requiring baseline histology for enrollment prior to randomization would have operational
implications as biopsy samples would need to be processed and centrally read within a
reasonable turnaround time after the screening colonoscopy. Alternatively, patients found
to lack baseline histopathologic inflammation could be excluded post-randomization in a
pre-specified modified intent-to-treat approach.
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A second concern was that imposing histologic requirements at baseline could further
restrict enrollment in UC trials. Given the discordance between endoscopic and histologic
findings in patients with UC,19 it is plausible that some patients who meet all other criteria
for enrollment would be excluded solely on the basis of absent histologic inflammation
(which may be related to sampling error alone). It was estimated from the personal
experience of the panellists that this situation could arise in approximately 10% of
cases.19-21 Hence, there was substantial discussion on the appropriate minimum threshold
and the panel was uncertain if baseline histology should be required to enroll patients with
otherwise moderate-to-severe disease. Selecting a higher threshold for enrolment may be too
restrictive, and therefore, a minimum of having at least mild neutrophilic inflammation was
chosen by the panel, recognizing that many patients will have more significant histologic
disease. There may also be a subset of patients with very mild histologic activity, who may
not have sufficient baseline disease to meet the suggested definitions of histologic response.
In these instances, reporting outcomes using continuous measures (e.g. mean change in
the Robarts Histopathology Index) should be considered. Nevertheless, qualifying patients
using histology as the primary entry criterion may facilitate participation in trials of patients
with mild-to-moderate UC, where the most common reason for screening failure is minimal
endoscopic inflammation and may additionally provide confidence that symptoms are due to
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UC rather than functional overlap. Additional research is required to understand the effect of
different baseline cut-offs of histologic activity on trial recruitment and readouts.
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We included only one statement in this exercise relating to the definition of ‘mucosal
healing’, which aimed to capture the current US regulatory recommendations that both
endoscopic and histologic disease activity should be assessed for labeling purposes.
However, the meaning of ‘mucosal healing’ has evolved and become ambiguous; in
clinical practice, it typically refers to endoscopic improvement (Mayo endoscopic subscore
[MES]=1) or endoscopic remission (MES=0) alone without consideration of histopathology.
Treatment effect sizes have been shown to vary when considering endoscopic vs. histologic
outcomes at the same timepoint.22 Therefore, we argue that ‘mucosal healing’ is an
insufficiently precise term to describe therapeutic response, both endoscopic and histologic
outcomes should be reported separately, and a more accurate descriptor such as “combined
endoscopic-histologic remission” or “histo-endoscopic remission” should be used when
reporting the composite endpoint. Understanding whether achieving endoscopic remission is
sufficient or whether targeting histologic remission will result in better short and long-term
outcomes is an important research priority, and a large multicenter clinical trial randomizing
patients to different therapeutic endpoints is currently recruiting (NCT04259138).
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There was agreement that the presence of neutrophilic infiltration is the most important
measure of histologic disease activity in UC. Conversely, the importance of measuring
eosinophils was less clear. Although some studies have suggested that mucosal eosinophilia
is a negative predictor of treatment response, the panel did not believe that there is
sufficient evidence to routinely require eosinophil measurement at this time.23, 24 While
a simpler definition of histologic remission based on the absence or presence of neutrophils
was considered, the panel discussed that a definition of histologic remission requiring
complete absence of neutrophilic inflammation may be too stringent to achieve with current
therapies, and that standardizing histologic assessment using formalized scoring tools is
an important priority for both clinical trials and in clinical practice. The Geboes Score,
Robarts Histopathology Index, and Nancy Index were considered appropriate instruments
for assessing disease activity and have been the most thoroughly evaluated instruments
in the literature. There are strengths and limitations to each scoring system and direct
comparisons of the operating properties between instruments remains a research priority. It
was recognized that the Geboes Score was originally designed as a classification scheme
and empirically converting it to either a 6-point or 22-point ordinal or continuous measure
based on the highest subscore needs validation. Although there was discussion that the
wider dynamic range of the Robarts Histopathology Index may provide a theoretical
advantage for measuring responsiveness compared to the Nancy Index, a post-hoc analysis
of biopsies collected in the TOUCHSTONE ozanimod trial by four blinded pathologists
demonstrated that the standardized effect size was similar across the Geboes Score, Robarts
Histopathology Index, Nancy Index, and modified Riley Score.25
Multiple definitions of histologic improvement and remission were considered by the panel.
In the phase III UNIFI program evaluating ustekinumab in patients with moderate-to-severe
UC, histologic improvement was defined as the composite of neutrophil infiltration in < 5%
of crypts, with no evidence of crypt destruction, erosions, ulcerations, or granulation tissue.
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Achieving this outcome was significantly associated with clinical remission and improved
disease activity scores at week 44.22 The corresponding Geboes Score (≤ 3.1) was voted as
an appropriate definition of histologic improvement by the panel. For histologic remission, a
stricter definition of complete elimination of mucosal neutrophils (Geboes < 2B.1 or Nancy
Index < 2) was voted as appropriate, which is consistent with several studies illustrating
the clinical benefits of achieving this target.26 However, there was less clarity on whether
chronic inflammatory changes in the lamina propria and architectural distortion should be
used in defining histologic targets for treatment. Recent studies have reported that patients
who achieve complete histologic normalization are at a reduced risk of clinical relapse
compared to patients without normalization.6, 27 Furthermore, Cushing et al. observed that
both architectural changes and chronic inflammatory infiltrate were predictive of disease
relapse within two years.27 However, the panel was unclear whether this is appropriate or
realistic to achieve with currently available therapies, particularly within the timeframe of an
8- to 12-week induction trial.
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Our study has several strengths. We included internationally recognized IBD
gastroenterologists and pathologists, with extensive experience in trial design and
histopathology interpretation. Additionally, we used rigorous methodology to combine the
best available evidence from the literature with the clinical expertise of the panel. Finally,
we addressed a broad range of issues pertaining to implementing histopathology in clinical
trials from biopsy acquisition to endpoint evaluation. However, we acknowledge some
important limitations. First, there were several items for which voting was primarily based
on expert opinion as there was limited empirical evidence to guide decision making. We
have highlighted these items throughout the discussion as areas of research priority. Second,
the modified RAND/UCLA method is not designed to force consensus. Therefore, there are
some items voted as appropriate which may seem contradictory to or overlapping with other
statements. For example, both segmental sampling and sampling from the worst affected
area 0 to 25 cm from the anal verge were rated as appropriate strategies. These statements
generally reflect topics of discrepancy where additional data are required to determine the
most appropriate method. Third, there was a high volume of complex statements given the
breadth of the scope of this initiative, and this may have potentially contributed to panelist
fatigue.
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In summary, we have developed a framework for appropriately integrating histopathology
assessment in UC clinical trials through an expert panel. Key conclusions include the
importance of assessing histopathology using a standardized biopsy acquisition and handling
protocol, measuring histologic activity using validated instruments at both enrollment and
endpoint adjudication, and incorporating histologic readouts in clinical trial endpoints
in accordance with regulatory guidance. These results can be used by sponsors and
regulators to help inform biopsy procurement strategies relevant to their drug development
program. We also highlight several research priorities. Additional studies are required to:
1) understand the relative performance characteristics of the different histology indices; 2)
compare treatment effects and explain the discrepancies between endoscopic and histologic
measurements of disease activity; 3) delineate the prognostic implications of varying
thresholds for defining histologic response and remission; 4) recognise the effect on trial
recruitment and readouts when minimum standards of histologic activity are required
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for enrolment; 5) determine whether achieving histological plus endoscopic remission is
casually related to superior outcomes compared to endoscopic remission alone; and 6)
maximize the efficiency of histopathology evaluation to facilitate the higher burden of
biopsy sampling that has been recommended.
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Refer to Web version on PubMed Central for supplementary material.
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IHC

immunohistochemistry

IL

Interleukin

JAK

Janus Kinase

MPO

Myeloperoxidase

TNF

Tumour Necrosis Factor
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WHAT YOU NEED TO KNOW
Background & Context:
Assessment of histopathology is essential for defining disease activity in UC. With
multiple novel therapies in development, guidance is required to standardize the
implementation of histopathology measures in UC clinical trials.
New Findings:
An international, interdisciplinary expert panel was convened to outline appropriate
biopsy acquisition protocols, histologic activity indices for disease evaluation, and
definitions of histologic outcomes for UC clinical trials.
Limitations:
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Some recommendations, such as requiring segmental biopsies and assessment of
histologic activity at enrollment, will pose operational challenges for trials that require
innovative, efficient solutions.
Impact:
Adopting a standardized framework for biopsy collection and consensus definitions of
histologic response and remission will improve the interpretation of these endpoints for
novel therapies in UC clinical trials.
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Standardization of biopsy acquisition in ulcerative colitis clinical trials.
Median
Panel Score
(IQR)

Rating

Histologic measurements are important to assess disease activity in UC

9 [8, 9]

Appropriate

Histologic measurements are important to determine therapeutic efficacy in clinical trials of UC

8 [8, 9]

Appropriate

A uniform biopsy strategy is needed to optimally measure disease activity in UC

9 [8, 9]

Appropriate

The endoscopic appearance of the mucosa should dictate from where biopsies are taken

7 [7, 9]

Appropriate

8 [6, 9]

Appropriate

8 [8, 9]

Appropriate

8 [8, 9]

Appropriate

The worst area in five segments (rectum, sigmoid, descending, transverse, and ascending) at all time
points if colonoscopy is performed

7 [7, 8]

Appropriate

The worst area in three segments (rectum, sigmoid, and descending) at all time points if sigmoidoscopy is
performed

7 [7, 8]

Appropriate

The worst affected area 15-25cm from the anal verge at all time points

7 [5, 7]

Appropriate

The worst affected area 0-25cm from the anal verge at all time points in order to include the rectum

8 [7, 8]

Appropriate

The worst affected area in the rectosigmoid at all time points

7 [6, 8]

Appropriate

If a certain area was biopsied at baseline, effort should be made to biopsy the same area at subsequent time
points (even if the mucosa looks improved or normal)

7 [5, 8]

Appropriate

If a certain area was biopsied at baseline, the biopsies at subsequent time points should be taken from the area
of worst endoscopic activity (even if this area is in a different location)

8 [7, 8]

Appropriate

An endoscopic tattoo should be performed to ensure the same area is biopsied at baseline and subsequent
timepoints

2 [1, 4]

Inappropriate

1 biopsy per segment/area biopsied

3 [1, 5]

Inappropriate

2 biopsies per segment/area biopsied

7 [6, 8]

Appropriate

3 biopsies per segment/area biopsied

7 [5, 8]

Appropriate

4 biopsies per segment/area biopsied

7 [3, 7]

Appropriate

5 biopsies per segment/area biopsied

3 [2, 5]

Inappropriate

8 weeks

7 [5, 8]

Appropriate

10 weeks

7 [5, 8]

Appropriate

12 weeks

7 [5, 8]

Appropriate

14 weeks

5 [5, 7]

Uncertain

16 weeks

5 [4, 7]

Uncertain

18 weeks

4 [3, 5]

Uncertain

20 weeks

4 [2, 5]

Uncertain

Item

Where to take biopsies

If an ulcer is present, all biopsies should be taken from the edge of the ulcer
If ulcers are not seen, but there are macroscopically abnormal areas, biopsies should be taken from the
most abnormal area
If the endoscopic appearance of the mucosa is normal, random biopsies should be taken
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Biopsies should be taken from:

Author Manuscript

The minimum number of biopsies necessary to measure disease activity in UC is:

When to take biopsies
For induction trials, biopsy procurement for histologic assessment of UC should ideally take place in relation
to randomization at:
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Median
Panel Score
(IQR)

Rating

8 [6, 9]

Appropriate

Standard biopsy forceps should be used to obtain biopsies

7 [7, 8]

Appropriate

Jumbo biopsy forceps should be used to obtain biopsies

6 [5, 8]

Uncertain

It is acceptable to take biopsies using one bite of the mucosa with one pass of a biopsy forceps

7 [5, 8]

Appropriate

It is acceptable to take biopsies using two bites of the mucosa with one pass of a biopsy forceps

7 [5, 8]

Appropriate

It is acceptable to take biopsies using three bites of the mucosa with one pass of a biopsy forceps

5 [4, 7]

Uncertain

Biopsies should be placed directly in 10% formalin with minimal tissue handling

8 [7, 9]

Appropriate

A minimum and maximum fixation time in formalin should be specified

7 [7, 9]

Appropriate

Biopsies should be fixed for a minimum of 6 hours and maximum of 36 hours to ensure maximum use of the
tissue (hematoxylin and eosin, immunohistochemistry, RNA, etc.)

7 [5, 8]

Appropriate

Proper orientation of the biopsies in the tissue block is necessary for accurate scoring

8 [7, 9]

Appropriate

Biopsies should be oriented such that the long axis of the colonic crypts is visualized in the tissue section

8 [7, 9]

Appropriate

Hematoxylin and eosin stained sections are sufficient for histologic evaluation of disease activity

8 [7, 9]

Appropriate

Immunohistochemistry to quantify various cell types should be performed to measure disease activity

4 [3, 5]

Uncertain

Immunohistochemistry can provide valuable additional information regarding disease activity but is not
required

7 [4, 8]

Appropriate

Myeloperoxidase expression by immunohistochemistry should be assessed in clinical trials of UC

5 [2, 5]

Uncertain

Item

Author Manuscript

For maintenance trials, biopsy procurement for histologic assessment of UC should take place in relation to
randomization at approximately 52 weeks
How to take and prepare biopsies
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IQR interquartile range
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Histologic items and indices to measure disease activity in ulcerative colitis clinical trials.
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Median
Panel Score
(IQR)

Rating

For each item measured, the score should be based on the biopsy fragment that generates the worst score for
that item

9 [7, 9]

Appropriate

For each item measured, the score should be based on the average involvement across all fragments

5 [4, 5]

Uncertain

It is important to measure degree of architectural change/distortion

7 [7, 8]

Appropriate

It is important to measure degree of lamina propria chronic inflammation (lymphocytes and plasma cells)

8 [7, 9]

Appropriate

It is important to measure degree of basal plasmacytosis

8 [6, 9]

Appropriate

It is important to measure degree of lamina propria eosinophils

5 [5, 7]

Uncertain

It is important to measure degree of lamina propria neutrophils

9 [8, 9]

Appropriate

It is important to measure degree of epithelial neutrophils

9 [8, 9]

Appropriate

It is important to measure degree of epithelial damage (including surface epithelial injury and crypt destruction)

9 [8, 9]

Appropriate

It is important to assess for the presence or absence of erosions

9 [8, 9]

Appropriate

It is important to assess for the presence or absence of ulcers

9 [8, 9]

Appropriate

Ulcers and erosions should be distinguished from one another

7 [5, 8]

Appropriate

The Geboes Score is an appropriate instrument for assessing histologic disease activity in UC

7 [7, 9]

Appropriate

The Geboes Score is an appropriate instrument for classifying histologic disease activity in UC (i.e.,
distinguishing patients with active vs. inactive disease)

8 [7, 9]

Appropriate

The Geboes Score is an appropriate instrument for measuring change in histologic disease activity in UC

7 [6, 8]

Appropriate

Converting the Geboes Score to a 0-6 scale (taking the highest Geboes subscore and assigning number 0-6) is
an appropriate instrument for assessing histologic disease activity in UC

7 [5, 7]

Appropriate

The continuous Geboes Score (where each subscore is given a number from 0-22 and the highest subscore is
used to assign the score) is an appropriate instrument for assessing histologic disease activity in UC

6 [5, 7]

Uncertain

The Robarts Histopathologic Index is an appropriate instrument for assessing histologic disease activity in UC

8 [7, 9]

Appropriate

The Robarts Histopathologic Index is an appropriate instrument for classifying histologic disease activity in UC
(i.e., distinguishing patients with active vs. inactive disease)

8 [7, 9]

Appropriate

The Robarts Histopathologic Index is an appropriate instrument for measuring change in histologic disease
activity in UC

8 [7, 9]

Appropriate

The Nancy Index is an appropriate instrument for assessing histologic disease activity in UC

7 [7, 8]

Appropriate

The Nancy Index is an appropriate instrument for classifying histologic disease activity in UC (i.e.,
distinguishing patients with active vs. inactive disease)

8 [8, 8]

Appropriate

The Nancy Index is an appropriate instrument for measuring change in histologic disease activity in UC

7 [5, 7]

Appropriate

The modified Riley score is an appropriate instrument for assessing histologic disease activity in UC

6 [5, 7]

Uncertain

The modified Riley score is an appropriate instrument for classifying histologic disease activity in UC (i.e.,
distinguishing patients with active vs. inactive disease)

6 [5, 8]

Uncertain

The modified Riley score is an appropriate instrument for measuring change in histologic disease activity in UC

6 [5, 7]

Uncertain

The Harpaz Index is an appropriate instrument for assessing histologic disease activity in UC

5 [5, 7]

Uncertain

The Harpaz Index is an appropriate instrument for measuring change in histologic disease activity in UC

5 [5, 7]

Uncertain

Item

Histologic items for measuring disease activity

Histologic indices for measuring disease activity
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Table 3.

Author Manuscript

Configuration of clinical trial histopathology endpoints and outcome definitions in ulcerative colitis clinical
trials

Author Manuscript
Author Manuscript
Author Manuscript

Median
Panel Score
(IQR)

Rating

Histologic activity in UC is defined by neutrophilic inflammation of the mucosa

8 [7, 9]

Appropriate

Histologic remission in UC is defined by absence of neutrophilic inflammation of the mucosa

8 [7, 9]

Appropriate

Histologic remission is an appropriate histologic endpoint

8 [7, 9]

Appropriate

Histologic remission is a realistic histologic endpoint

7 [7, 8]

Appropriate

The criteria for histologic remission should be the same in trials of mild-to-moderate UC compared to trials of
moderate-to-severe UC

7 [7, 9]

Appropriate

Histologic improvement is an appropriate histologic endpoint

8 [7, 9]

Appropriate

Histologic improvement is a realistic histologic endpoint

8 [8, 9]

Appropriate

Histologic improvement is best defined as a Geboes Score ≤ 3.1 (< 5% neutrophils in epithelium)

7 [5, 7]

Appropriate

Histologic improvement is best defined as a Robarts Histopathologic Index score ≤ 6

7 [5, 7]

Appropriate

Histologic improvement is best defined as a Robarts Histopathologic Index score ≤ 9

5 [5, 7]

Uncertain

Histologic improvement is best defined as a ≥ 7-point reduction in the Robarts Histopathologic Index score
from baseline

6 [5, 7]

Uncertain

Histologic improvement is best defined as a ≥ 1-point reduction in the Nancy Score from baseline

7 [6, 7]

Appropriate

Histologic improvement is best defined as a 50% reduction from baseline in the Robarts Histopathologic Index

7 [5, 8]

Appropriate

Histologic improvement is best defined as a decrease (any amount) in the histologic score from baseline

5 [4, 6]

Uncertain

Change in histology score is an appropriate endpoint

8 [7, 9]

Appropriate

Change in histology score is a realistic endpoint

8 [7, 9]

Appropriate

Histology should be part of the primary endpoint in clinical trials of UC

7 [5, 9]

Appropriate

Histology should be a secondary endpoint in clinical trials of UC

8 [7, 9]

Appropriate

Mucosal healing should be defined as endoscopic improvement and histologic remission

8 [7, 9]

Appropriate

When assessing change in disease activity between time points in a given subject, a direct comparison of the
biopsies should be performed as long as the pathologist/reader is blinded to timepoint and treatment arm

6 [4, 7]

Uncertain

A minimum histological disease activity score at baseline should be required for enrollment into all UC clinical
trials regardless of disease severity

8 [7, 9]

Appropriate

A minimum histological disease activity score at baseline should be required for enrollment into all UC clinical
trials for patients with mild-moderate disease only

7 [5, 8]

Appropriate

A minimum histological disease activity score at baseline should be required for enrollment into all UC clinical
trials for patients with moderate-severe disease only

6 [4, 8]

Uncertain

At baseline, there should be at least neutrophilic inflammation of the epithelium (Geboes ≥ 3.1)

8 [7, 9]

Appropriate

At baseline, the minimum Robarts Histopathologic Index score should be ≥ 4

7 [5, 8]

Appropriate

At baseline, the minimum Nancy Index should be ≥ 2

8 [5, 8]

Appropriate

7 [6, 7]

Appropriate

Item
Histology outcome configurations and definitions

Baseline histologic disease activity requirements

Appropriate and realistic histologic endpoints
Absence of neutrophilic inflammation in the mucosa (Geboes <2B.1, Nancy <2) is an appropriate histologic
endpoint in UC:
At the end of the induction therapy period
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Median
Panel Score
(IQR)

Rating

7 [7, 8]

Appropriate

At the end of the induction therapy period

7 [5, 7]

Appropriate

At the end of the maintenance therapy period

7 [7, 8]

Appropriate

At the end of the induction therapy period

6 [5, 7]

Uncertain

At the end of the maintenance therapy period

6 [5, 7]

Uncertain

At the end of the induction therapy period

6 [5, 7]

Uncertain

At the end of the maintenance therapy period

6 [6, 7]

Uncertain

At the end of the induction therapy period

5 [5, 7]

Uncertain

At the end of the maintenance therapy period

6 [5, 7]

Uncertain

At the end of the induction therapy period

5 [5, 7]

Uncertain

At the end of the maintenance therapy period

6 [5, 7]

Uncertain

At the end of the induction therapy period

5 [4, 6]

Uncertain

At the end of the maintenance therapy period

6 [5, 7]

Uncertain

At the end of the induction therapy period.

5 [3, 5]

Uncertain

At the end of the maintenance therapy period.

5 [4, 6]

Uncertain

Item

Author Manuscript

At the end of the maintenance therapy period
Absence of neutrophilic inflammation in the mucosa (Geboes <2B.1, Nancy <2) is a realistic histologic
endpoint in UC:

Absence of neutrophilic inflammation in the mucosa and normal to only mild increase in lamina propria chronic
inflammation (Geboes: 0.0-0.3, 1.0-1.1, 2A.0-2A.3, 2B.0, 3.0, 4.0, 5.0) is an appropriate histologic target:

Absence of neutrophilic inflammation in the mucosa and normal to only mild increase in lamina propria chronic
inflammation (Geboes: 0.0-0.3, 1.0-1.1, 2A.0-2A.3, 2B.0, 3.0, 4.0, 5.0) is a realistic histologic target:

Author Manuscript

Absence of neutrophilic inflammation in the mucosa, normal to only a mild increase in lamina propria chronic
inflammation, and normal to only a mild increase in lamina propria eosinophils (Geboes: 0.0-0.3, 1.0-1.1,
2A.0-2A.1, 2B.0, 3.0, 4.0, 5.0) is an appropriate histologic target:

Absence of neutrophilic inflammation in the mucosa, normal to only a mild increase in lamina propria chronic
inflammation, and normal to only a mild increase in lamina propria eosinophils (Geboes: 0.0-0.3, 1.0-1.1,
2A.0-2A.1, 2B.0, 3.0, 4.0, 5.0) is a realistic histologic target:

Complete histologic normalization (Geboes: 0.0, 1.0, 2A.0, 2B.0, 3.0, 4.0, 5.0) is an appropriate histologic
target

Author Manuscript

Complete histologic normalization (Geboes: 0.0, 1.0, 2A.0, 2B.0, 3.0, 4.0, 5.0) is a realistic histologic target

Author Manuscript
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